Ask AI
Back Back
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Transforming Lymphoma With CAR T-cell Therapy

Clinical Thought

Experts answer your questions related to the program, “Transforming Lymphoma Management: Practical Integration of CAR T‑Cell Therapies for Improved Outcomes.” This social media forum provides you with ongoing access to experts for your questions and challenging cases before, during, and after the associated satellite symposium at SOHO 2026.

Released: July 16, 2026

Review Activity

Share

Faculty

Caron Jacobson

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Krish Patel

Krish Patel, MD

Executive Director, Hematologic Cancer Research
Director, Lymphoma Research Program
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee
Jason Westin

Jason Westin, MD, MS, FACP, FASCO

Professor, Department of Lymphoma & Myeloma
Lead, Lymphoma & Myeloma Service Line
Director, Lymphoma Clinical Research
MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, physician assistants, nurse practitioners, clinical nurse specialists, nurses, pharmacists, and other healthcare professionals who care for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Demonstrate the ability to select appropriate candidates for CAR T-cell therapy in DLBCL, FL, MCL, MZL, and CLL/SLL, applying current evidence and FDA-approved indications

  • Construct comprehensive care plans for patients undergoing CAR T-cell therapy, including referral, pre-treatment preparations, and post-treatment monitoring

  • Formulate evidence-based management strategies for CAR T-cell therapy-related adverse events, including cytokine release syndrome and neurotoxicity

  • Evaluate ongoing clinical trials and emerging data on CAR T-cell therapies for B-cell malignancies to guide appropriate patient enrollment and integrate new findings into clinical practice

Financial Disclosures

Primary Author

Caron Jacobson, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, Autolus, Bristol Myers Squibb, Caribou, Galapagos, Genentech, Genmab, Kite, Kyverna, Lyell, Miltenyi, Novartis, Roche, Umoja.

Krish Patel, MD: researcher (paid to institution): AbbVie, Adaptive, Adicent, Arvinas, AstraZeneca, Bristol Myers Squibb, CRISPR, Fate, Genentech/Roche, Kite, Indapta, Janssen, Lilly, Loxo Oncology, MEI Pharma, Merck, Nurix, Pfizer, Pharmacyclics, Sana, Xencor; consultant/advisor (paid to institution): AbbVie, Adaptive, ADC Therapeutics, Arcus, AstraZeneca, Avencell, BeOne, BicycleTx, BioNTech, Bristol Myers Squibb, Caribou, Century, Foresight Diagnostics, Genentech/Roche, Genmab, Immunome, Janssen, Kyverna, Legend, Lilly, Lyell, Merck, Sanofi; consultant/advisor: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou, Genentech/Roche, Kite, Lilly, Merck, Pfizer; speaker: Bristol Myers Squibb, Kite.

Jason Westin, MD, MS, FACP, FASCO: researcher: ADC Therapeutics, Allogene, AstraZeneca, Bristol Myers Squibb, Incyte, Kite/Gilead, Novartis, Nurix, Roche/Genentech; consultant/advisor/speaker: AbbVie, ADC Therapeutics, Allogene, AstraZeneca, Bristol Myers Squibb, Chugai, Incyte, Janssen, Lilly, Lyel.